AU2020329290A1 - Engineered interleukin-2 receptor beta agonists - Google Patents

Engineered interleukin-2 receptor beta agonists Download PDF

Info

Publication number
AU2020329290A1
AU2020329290A1 AU2020329290A AU2020329290A AU2020329290A1 AU 2020329290 A1 AU2020329290 A1 AU 2020329290A1 AU 2020329290 A AU2020329290 A AU 2020329290A AU 2020329290 A AU2020329290 A AU 2020329290A AU 2020329290 A1 AU2020329290 A1 AU 2020329290A1
Authority
AU
Australia
Prior art keywords
engineered
polypeptide
seq
substitution
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020329290A
Other languages
English (en)
Inventor
Yan Chen
Samuel Clement HASSAN
Ning Jiang
Nathan KALLEN
Jenna NGUYEN
Christina SWANSON
Kehao Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elpis Biopharmaceuticals Corp
Original Assignee
Elpis Biopharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elpis Biopharmaceuticals Corp filed Critical Elpis Biopharmaceuticals Corp
Publication of AU2020329290A1 publication Critical patent/AU2020329290A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2020329290A 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists Pending AU2020329290A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962886148P 2019-08-13 2019-08-13
US62/886,148 2019-08-13
PCT/US2020/046244 WO2021030633A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Publications (1)

Publication Number Publication Date
AU2020329290A1 true AU2020329290A1 (en) 2022-03-24

Family

ID=72243240

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020329290A Pending AU2020329290A1 (en) 2019-08-13 2020-08-13 Engineered interleukin-2 receptor beta agonists

Country Status (8)

Country Link
US (1) US20230002466A1 (https=)
EP (1) EP4013774A1 (https=)
JP (2) JP7783164B2 (https=)
KR (1) KR20220044534A (https=)
CN (1) CN114787182A (https=)
AU (1) AU2020329290A1 (https=)
CA (1) CA3147677A1 (https=)
WO (1) WO2021030633A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
CA3169095A1 (en) * 2020-03-05 2021-09-10 Kenan Christopher GARCIA Designed il-2 variants
WO2022115865A2 (en) 2020-11-25 2022-06-02 Xilio Development, Inc. Tumor-specific cleavable linkers
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
CN113603791A (zh) * 2021-08-11 2021-11-05 厦门目青股权投资合伙企业(有限合伙) 一种融合蛋白及其应用
CN119731199A (zh) * 2022-05-10 2025-03-28 艾佩斯瑞生物制药公司 工程化的白细胞介素-2受体β降低结合的激动剂
WO2025010341A2 (en) * 2023-07-05 2025-01-09 The Trustees Of Dartmouth College Cytokine hybrid proteins and methods related thereto

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
SG192673A1 (en) * 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CN109535259A (zh) * 2012-12-05 2019-03-29 生控基因疫苗股份有限公司 用作诱发抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
WO2015164815A1 (en) * 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
MX2021000801A (es) * 2018-07-24 2021-04-12 BioNTech SE Agonistas de il2.

Also Published As

Publication number Publication date
JP2026032136A (ja) 2026-02-25
WO2021030633A1 (en) 2021-02-18
JP2022544785A (ja) 2022-10-21
CA3147677A1 (en) 2021-02-18
CN114787182A (zh) 2022-07-22
US20230002466A1 (en) 2023-01-05
JP7783164B2 (ja) 2025-12-09
EP4013774A1 (en) 2022-06-22
KR20220044534A (ko) 2022-04-08

Similar Documents

Publication Publication Date Title
JP7783164B2 (ja) 改変インターロイキン２受容体ベータアゴニスト
US11208459B2 (en) Constructs having a SIRP-alpha domain or variant thereof
JP7098725B2 (ja) 二重特異性２＋１コントースボディ
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP7148539B2 (ja) 免疫抱合体
JP6464255B2 (ja) 二重特異性ｔ細胞活性化抗原結合分子
CN103492411B (zh) 突变体白介素-2多肽
JP2021528988A (ja) 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
US20240376171A1 (en) Protease-activated polypeptides
JP2025500949A (ja) アゴニストｌｔｂｒ抗体及びそれらを含む二重特異性抗体
WO2022117692A2 (en) Ph-dependent mutant interleukin-2 polypeptides
AU2022387275A1 (en) Immunotherapeutic proteins comprising an fc region component with a mutation at position 429
US20250326813A1 (en) Engineered interleukin-2 receptor beta reduced-binding agonist
HK40076453A (en) Engineered interleukin-2 receptor beta agonists
HK40102926A (zh) 带电荷对的双特异性抗体及其应用
CN118510802A (zh) Cd20-pd1结合分子及其使用方法
HK40078517A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
HK1257372B (zh) 具有SIRP-α结构域或其变体的构建体